Innovative Therapies in the Treatment of Hypertrophic Cardiomyopathy: A Literature Review on the Use of Mevacamten
Innovative Therapies in the Treatment of Hypertrophic Cardiomyopathy: A Literature Review on the Use of Mevacamten
-
DOI: 10.22533/at.ed.12523041221
-
Palavras-chave: miocardiopatia hipertrófica, mevacamten, tratamento, espessamento cardíaco, eficácia.
-
Keywords: hypertrophic cardiomyopathy, mavacamten, treatment, cardiac thickening, efficacy.
-
Abstract: Hypertrophic cardiomyopathy (HCM) is a hereditary cardiac disease characterized by abnormal thickening of the heart muscle, particularly in the left ventricle. This literature review aims to explore the use of mavacamten as an innovative therapy in the treatment of HCM. Twenty relevant studies, including clinical trials and preclinical research, were reviewed. The results demonstrated the promising efficacy of mavacamten in reducing cardiac thickening and improving symptoms in HCM patients. Although well-tolerated, additional studies with larger samples and long-term follow-up are needed to establish its safety and effectiveness. Mavacamten represents a promising therapeutic option for HCM patients, opening new perspectives for treating this complex cardiac disease.
- Germana Furtado da Graça Cezar
- Guilherme Machado Carvalheira
- Francyane Peixoto Ramos de Abreu
- Valentina Morelli Barbosa
- Luana Gomes Dias Pimentel
- Paulo Roberto Hernandes Júnior
- Juliana de Souza Rosa
- Nathan Noronha Fidelis Hernandes
- Rossy Moreira Bastos Junior
- Paula Pitta de Resende Côrtes
